X

Ind-Swift Ltd Stock Analysis

Small Cap
Evaluated by 210 users | BSE: 524652 | NSE: INDSWFTLTD |
Pharmaceuticals & Drugs
Ind-Swift Limited was incorporated as a public limited company on June 6, 1986 under the Companies Act 1956.It is the flagship company of India based Ind Swift Group. Ind-Swift Limited is a north India based pharmaceutical company.Ind Swift Group is a legendary forename in the world Class...

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Value Creation
 Mar'11Jun'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20
Return on Capital Employed 10.89%6.55%-4.09%-5.24%-11.06%-20.66%-27.5%-6.65%-2.45%-1.1%
Growth Parameters
Growth Parameters Colour Code Guide
Net Sales (Rs. Cr.) 8761,272524570417304263270289330
Y-o-Y Gr. Rt.-45.2%-58.8%8.7%-26.8%-27.1%-13.6%2.6%7.1%14%
Adjusted EPS (Rs.) 10.31-2.97-31.2-22.68-28.82-39.71-33.7-6.47-2.09-5.19
Y-o-Y Gr. Rt.--128.8%NANANANANANANANA
Book Value per Share (Rs.) 69.4943.0543.5110.87-16.16-53.68-115.43-125.43-124.94-131.66
Adjusted Net Profit 43.5-13.7-144-114-145-200-183-35.1-11.3-28.1
Net Op. Cash Flow (Rs. Cr.) 59.975.3-19510385.6-1066.71.342.834.6
Debt to Cash Flow from Ops 9.898.71-6.649.8312.15-9.89156788.6223.629.39
Standalone financials take only the parent company into account while consolidated financials take into account financials of the parent company as well as of all its subsidiaries. In most companies consolidated financials should be used for analysis.
Ind-Swift Ltd. should be analysed on a Standalone basis
CAGR
CAGR Colour Code Guide
  9 yrs 5 yrs 3 yrs 1 yr
Net Sales -10.3%-4.6%7.8%14%
Adjusted EPS -192.7%NANANA
Book Value per Share -207.4000
Share Price -18.5% -3.1% -16.1% 57.5%
Key Financial Parameter
Performance Ratio Colour Code Guide
 Mar'11Jun'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20
Return on Equity (%) 14.33-5.27-40.14-70.13-421.32143.3442.935.431.674.05
Operating Profit Margin (%) 12.726.08-4.48-5.65-16.76-51.57-24.862.933.737.11
Net Profit Margin (%) 4.96-1.08-27.49-20.04-34.78-65.7-69.39-12.99-3.92-8.54
Debt to Equity 1.933.125.8914.65-15.49-4.09-1.72-1.55-1.49-1.43
Working Capital Days 297204835537686799602355317298
Cash Conversion Cycle 182100481325391450195-44-89-98
Entity Percentage Holding
Promoters 55.55%
Institutions 1.77%
Non-Institutions 42.68%
Pledged *73.4673.4673.4673.4673.4673.4673.4673.4673.4673.46
* Pledged shares as % of Promoter's holding (%)
Data is not available for this company.

The 5-year analysis of Ind-Swift Ltd's performance infers:

Ind-Swift Ltd earnings have grown by 0%, whereas share price has depreciated -3.1% CAGR over the past five years, indicating the company's share price is likely undervalued. However, for specific investment actions please connect with your investment advisor.

We analysed the performance of Ind-Swift Ltd share prices over the last 10 years. Here is what we found out:

Ind-Swift Ltd share price has depreciated -18.7% annually over the past ten years.

Ind-Swift Limited was incorporated as a public limited company on June 6, 1986 under the Companies Act 1956.It is the flagship company of India based Ind Swift Group. Ind-Swift Limited is a north India based pharmaceutical company.

Ind Swift Group is a legendary forename in the world Class Pharmaceutical Industry who has broaden its horizons by plucking profound & sparkling footprints on multifarious diversified fronts, whilst going steadily and surely, scripting a success story filled

Ind-Swift Limited was incorporated as a public limited company on June 6, 1986 under the Companies Act 1956.It is the flagship company of India based Ind Swift Group. Ind-Swift Limited is a north India based pharmaceutical company.

Ind Swift Group is a legendary forename in the world Class Pharmaceutical Industry who has broaden its horizons by plucking profound & sparkling footprints on multifarious diversified fronts, whilst going steadily and surely, scripting a success story filled with enviable milestones and pioneering breakthroughs and has subsequently emergent as a group with an annual turn over of 1000 Crore.

Manufacturing of Pharmaceutical finished dosage are carried out at 7 state-of-the art manufacturing facilities which are second to the none are duly certified and approved by WHO GMP, spread over an area of 12, 00, 000 sq. ft. with manufacturing capacities confirming to stringent TGA/MHRA approvals; possessing an installed capacities of 3 billion units comprising tablets, capsules, ointments, injectables, liquids & dry syrup (all latest formulations with a marketing network.

Business areas of the company are:

Ind-Swift manufactures and markets finished dosage forms, through its different divisions, focusing on the needs of various therapeutic segments. The divisions include the following:Super Speciality, Animal Division, Daignozis, Institutions, Agile, Bio Sciences, Ethical, Health Care, Max Care, Mega care, Neuro and Resurgence

The company is also in health Publications- With the maiden issue in September, 2002; Ind-Swift’s Health Publication TRENDZ brings the latest in medical field to the medical fraternity. Routinely published four times a year, each issue of TRENDZ is devoted to important contemporary healthcare issues and medical issues of a particular specialty.

Ind Swift is known for it's reverse engineering ability with highly focused R & D capabilities (duly approved by Department of Science & Technology, Govt. of India) and is equipped with state-of-the-art equipment, facilities and talented pool of scientists and researchers.

  • A well accepted expertise in NDDS, in India and the world over.
  • A US patent for Clarie OD, with a market size of $300 million.
  • Another patent for Fexofenadine ODT with a market size of $2.5 billion.
  • Development of 10 new molecules with a market size of $6 billion.

Ind Swift’s efforts and achievements in taste masking of macrolides was India's first and remains the only feat of its kind in the country. The R &D department is also involved in creating international opportunities and alliances for CRAMS business, contributing significantly to the company's profitability. It also offers complete support to international partners for preparing and filing dossiers for finished dosages. By taking giant strides on roads less traveled, Ind-Swift has become one of India's fastest growing pharmaceutical companies.

Ind Swift has radianced up in infrastructures business in the name and style of “Ind Swift Infrastructures and developers Ltd, and has come up with a multi crore project named “Regalia Towers”, of course a society with 2 bedroom /3 bedroom flats and penthouses owing a mystique which is exemplary in itself which not only reflects a diversified transformative spell to infrastructures front but a unique state of art with the best of specifications also. In infrastructures, Ind Swift plans to be emergent with motels & Resorts project in the upcoming phases.

Awards/ Achievements

  • Ranked as one of the most promising pharmaceutical group in India by Express Pharma Pulse.
  • All India achievers award as legend in Business house category.
  • An ISO 9001, 2000 company.
  • Achieved Pharma Pulse award as fastest growing & most promising pharmaceutical company for three successive years.
Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323

Callback